Details for New Drug Application (NDA): 210169
✉ Email this page to a colleague
NDA 210169 describes VALGANCICLOVIR HYDROCHLORIDE, which is a drug marketed by Actavis Labs Fl Inc, Ajanta Pharma Ltd, Appco, Aurobindo Pharma, Granules, Hetero Labs Ltd V, MSN, Aurobindo Pharma Ltd, Cipla, Dr Reddys, Norvium Bioscience, Somerset Theraps Llc, and Strides Pharma, and is included in sixteen NDAs. It is available from nineteen suppliers. Additional details are available on the VALGANCICLOVIR HYDROCHLORIDE profile page.
The generic ingredient in VALGANCICLOVIR HYDROCHLORIDE is valganciclovir hydrochloride. There are seventeen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the valganciclovir hydrochloride profile page.
The generic ingredient in VALGANCICLOVIR HYDROCHLORIDE is valganciclovir hydrochloride. There are seventeen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the valganciclovir hydrochloride profile page.
Summary for 210169
| Tradename: | VALGANCICLOVIR HYDROCHLORIDE |
| Applicant: | Msn |
| Ingredient: | valganciclovir hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 210169
| Mechanism of Action | DNA Polymerase Inhibitors |
Suppliers and Packaging for NDA: 210169
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| VALGANCICLOVIR HYDROCHLORIDE | valganciclovir hydrochloride | FOR SOLUTION;ORAL | 210169 | ANDA | MAJOR PHARMACEUTICALS | 0904-7419 | 0904-7419-04 | 1 BOTTLE in 1 CARTON (0904-7419-04) / 100 mL in 1 BOTTLE |
| VALGANCICLOVIR HYDROCHLORIDE | valganciclovir hydrochloride | FOR SOLUTION;ORAL | 210169 | ANDA | airis PHARMA PVT LTD | 71151-003 | 71151-003-01 | 100 mL in 1 BOTTLE, DISPENSING (71151-003-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SOLUTION;ORAL | Strength | 50MG/ML | ||||
| Approval Date: | Feb 17, 2022 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
